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1. Introduction
The demonstration in the 1960's that cis-diamminedichloroplatinum(II), or cisplatin, inhibits
cellular division of Escherichia coli1 led to the subsequent discovery that this simple
coordination compound is also an effective antitumor agent in mouse models.2 Subsequent
studies validated cisplatin as an effective anticancer agent in humans as well,3–7 and FDA
approval of cisplatin for the treatment of metastatic ovarian and testicular cancers was
granted in 1978.8 Its introduction as a chemotherapeutic agent significantly improved the
survival outlook for many cancer patients; the cure rate for testicular cancer before the
approval of cisplatin was less than 10%, significantly lower than the 90% cure rate attained
with modern platinum chemotherapy.9,10
Cisplatin kills cancer cells primarily by cross-linking DNA and inhibiting transcription.11
The chemical origin of this process begins when cisplatin enters the cell and undergoes
aquation involving loss of one or both chloride ligands. The resulting platinum(II) aqua
complexes are potent electrophiles that readily react with a number of biological ligands
with loss of the bound water molecules. The purine bases of nucleic acids are strongly
nucleophilic at the N7 position. Thus, cisplatin binds readily to DNA, forming primarily
bifunctional adducts with loss of both chloride ligands. The major cisplatin-DNA adduct is
the intrastrand 1,2-d(GpG) cross-link, which accounts for 60–65% of the bound platinum.12
The resulting Pt-DNA adducts, which distort and bend the DNA structure,13–15 impede
transcription.16 The downstream effects of transcription inhibition ultimately lead to cell
death.
Despite its great curative success in testicular cancer, cisplatin is not universally effective in
other cancer types and induces a number of toxic side effects.17–19 Additionally, certain
cancers are resistant to cisplatin therapy. This resistance is either intrinsic or developed
during prolonged treatment.20,21 To circumvent these problems, new platinum complexes
have been pursued and investigated for their antitumor properties. Although well over a
thousand complexes have been prepared and tested thus far,22 only two other platinum drugs
are approved for clinical use worldwide, and three additional compounds are approved for
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regional use in Asia.23 These complexes, displayed in Chart 1, operate with a mechanism of
action similar to that of cisplatin, which involves DNA binding and transcription inhibition.
In designing a new platinum anticancer agent, several structural features can be strategically
modified. As shown in Figure 1, three different ligand types generally comprise a platinum
anticancer complex. The ligands L are typically nitrogen donors. They are referred to as
“non-leaving group” ligands because they form thermodynamically stable bonds with
platinum and are retained in the final platinum-DNA adduct. Modifications of these ligands
directly affect the nature of the resulting platinum-DNA adducts24–26 and therefore the
manner by which cellular repair pathways respond to those adducts. Complexes that contain
amine ligands different from the ammines in cisplatin usually exhibit a different spectrum of
activity in cancer cell lines and are usually not cross-resistant with cisplatin.27 Oxaliplatin,
with its chelating and chiral 1,2-diaminocyclohexane ligand, trans-1R,2R-DACH (DACH),
falls into this category. Modifications of the leaving group ligands X, so named because they
are lost upon DNA-binding, can alter the overall reaction stoichiometry and aquation
kinetics for a platinum anticancer complex. Complexes that react quickly, such as those with
labile nitrate ligands, are generally more toxic because of indiscriminate binding to off-
target biological nucleophiles.28 Carboplatin, on the other hand, contains a relatively stable
chelating CBDCA (CBDCA = 1,1-cyclobutane–dicarboxylato) ligand as its leaving group.
By comparison to cisplatin, carboplatin can be administered at higher doses because of its
lower toxicity profile.29,30 Although less toxic, carboplatin has a similar spectrum of activity
and exhibits cross-resistance to cisplatin, which is a result of the same non-leaving group
ammine ligands.27,31 The axial ligands R comprise the third category. Axial ligands are
present only in higher-valent platinum complexes, such as those of platinum(III) and
platinum(IV). These ligands can ultimately dissociate after biological reduction of the
platinum complex, although there is no guarantee that reduction will lead to their specific
departure from the coordination sphere. They provide convenient points for installation of
tumor-targeting moieties or attachment to nanoparticles. Any of the three ligand types can
be modified in order to alter the lipophilicity and water solubility of the resulting platinum
complex. Both of these properties are important in the design of an effective drug. The
stereochemistry and the number of each respective ligand type can be altered as well.
In this review, we present an overview of known synthetic strategies for the synthesis of
platinum anticancer complexes. Previous review articles have focused on the mechanistic
details of platinum-based drugs at the cellular level,32–37 the chemistry of platinum under
biological conditions,38,39 and new trends for the rational design of platinum anticancer
agents.40–46 The present article provides synthetic inorganic chemists with practical advice
on the synthesis and purification of potential platinum anticancer agents. The coordination
chemistry principles employed for the preparation of such compounds are emphasized and
are therefore useful to a broader readership. There are two major sections, which describe
the synthesis of platinum(II) and platinum(IV) complexes. These sections are further divided
based on the nature and stereochemistry of the target complexes. In each section, a short
overview is provided of the anticancer properties of the target complexes. Multinuclear
platinum complexes, some of which are excellent drug candidates,47,48 have been omitted
from this review to maintain the focus on single-site reactivity. The reaction schemes do not
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display fully balanced chemical reactions, but instead illustrate only the major platinum-
containing products. This choice stems from the complexity of many seemingly simple
reactions of platinum compounds, the chemistry of which can be deceptively complicated.
Two generic ligand types, L and X, are utilized (Figure 1), with ligands symbolized by “L”
representing either an amine or N-heterocyclic unit. When “(L2)” is used, the ligand is
bidentate. Ligands designated with an “X” are monoanionic, like halides or carboxylates.
2. Synthesis of Platinum(II) Complexes
All clinically used platinum drugs (Chart 1) contain the element in the +2 oxidation state
having almost exclusively square-planar coordination geometries. The major reaction
pathways involved in the synthesis of platinum(II) and other square-planar d8 complexes
involve associative ligand substitution. These reactions proceed through five-coordinate
trigonal-bipyramidal intermediates. The stereochemistry of the resulting products is dictated
by the relative trans effect of the ligands within the complex. Synthetic strategies discussed
in the following sections therefore rely heavily on the trans effect principle. For more
detailed summaries of substitution reactions of platinum(II) and other d8 complexes, as well
as the trans effect, the reader is referred elsewhere.49–51 An early review on the synthesis of
monodentate amine complexes of platinum(II) is also available.52
2.1. Synthesis of cis- and trans-[PtL2X2] Complexes
cis- and trans-Diamminedichloro–platinum(II), are stereoisomers, representative members
of the class of complexes having the general formula [PtL2X2], where L is an am(m)ine or
N-heterocycle and X is a halide or other labile ligand. Both cisplatin and its trans isomer
were first prepared over 100 years ago by Peyrone and Reiset, respectively,53,54 and were
commonly known as Peyrone's chloride and Reiset's second chloride. Cisplatin and the trans
isomer, both yellow solids, were recognized to be isomers of Magnus' green salt, [Pt(NH3)4]
[PtCl4]. Structural differences between these three compounds helped validate Werner's
theory of coordination chemistry.55
Following Peyrone's initial preparation of cisplatin, several different synthetic routes have
been described. The common starting material for these procedures is K2[PtCl4], a water-
soluble salt, which can be prepared directly from platinum metal in two steps.56 As with
Peyrone's initial synthesis, several protocols for the synthesis of cisplatin involve the direct
action of aqueous ammonia on the tetrachloroplatinate ion.57,58 This reaction inevitably
results in the formation of Magnus' green salt and the trans isomer as undesired byproducts,
both of which must be removed by additional purification steps.57,58 Recently, the use of
microwave irradiation for the synthesis of cisplatin directly from K2PtCl4 and NH4OAc was
reported.59 The adaptation of this method with flow chemistry techniques enables cisplatin
to be synthesized on the gram scale in one step with no contaminating impurities from
Magnus' green salt or the trans isomer.
The most widely used method for preparing cisplatin is that reported by Dhara in 1970.60
For this multistep reaction (Scheme 1), aqueous [PtCl4]2− is first converted to [PtI4]2− upon
treatment with 4 equiv of KI. The addition of ammonium hydroxide to the dark brown
solution of [PtI4]2− yields the yellow precipitate, cis-[Pt(NH3)2I2]. Removal of the iodide
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ligands from this complex with 2 equiv of AgNO3 in water gives the diaqua cation, cis-
[Pt(NH3)2(OH2)2]2+, from which isomerically pure cisplatin can be isolated as a yellow
solid following treatment with excess chloride ion. The absence of the trans isomer is
attributed to the much higher trans effect of the iodide compared to that of the chloride
ligand. The key intermediate in the formation of cisplatin from the tetrahaloplatinate anions
is the monosubstituted complex, [Pt(NH3)X3]−. When X is I, the large trans effect ensures
that the next NH3 ligand departs from a position trans to an iodide to give the desired cis
isomer. When X is Cl, the lower trans effect of the latter renders substitution trans to NH3
kinetically competitive with substitution trans to the halide, thus yielding a small proportion
of the trans isomer. Dhara's method has been adapted to prepare cis complexes with other
amine or N-heterocyclic ligands,61–63 cisplatin with 15N-labeled am–mines,64–66 and
radiolabeled 195mPt-cisplatin.67 When chelating diamines are used, this method is preferred
as well.68,69 In cases where the desired amine or N-heterocyclic ligands are not water-
soluble, an alternative synthetic route is employed, involving the addition of 2 equiv of the
amine ligand to K2PtCl4 in a solvent mixture of water and an alcohol at elevated
temperatures.70–73 The use of DMF instead of ethanol or methanol as a cosolvent for this
reaction has also been reported.74,75
Purification of cisplatin can be accomplished by recrystallization from hot water containing
either 0.1 M HCl or 0.9% NaCl.66,67 The high chloride ion concentration inhibits the
formation of platinum aqua or hydroxo complexes. The use of amide solvents to
recrystallize cisplatin is also an effective means of purification.76 Dissolution of cisplatin in
N,N-dimethylacetamide (DMA) to a concentration of 18 mg/mL, followed by the addition of
three volume equiv of 0.1 N HCl and incubation in an ice bath, affords analytically pure
material.67 Alternatively, storing a concentrated solution (~22 mg/mL) of cisplatin in DMF
at 3 °C overnight yields yellow cube-like crystals of a DMF solvate, cisplatin·DMF.77
Removal of DMF from the crystal lattice under vacuum gives solvent-free cisplatin of very
high purity.77 Care should be taken when recrystallizing new complexes of the general
formula, cis-[PtL2Cl2], from hot solvents. Although not observed for cisplatin, several other
compounds having this formula isomerize upon recrystallization from hot acetone or DMF,
giving instead the pure trans isomer.78–80 Thus, stereochemistry should be confirmed after
each purification step.
A quick way to test for the presence of isomeric impurities in cisplatin, its trans isomer, or
related [PtL2Cl2] complexes is the Kurnakow test.18 This test is performed by adding an
excess of thiourea (tu) to an aqueous mixture of cis/trans-[Pt(NH3)2Cl2]. The trans isomer
converts to a white, poorly water-soluble powder, trans-[Pt(NH3)2(tu)2]Cl2, whereas
cisplatin becomes the yellow, soluble complex [Pt(tu)4)]Cl2 (Scheme 2). The formation of
different products from the two isomers is a consequence of the high trans effect of thiourea.
The first equiv of thiourea displaces a chloride ligand. For cisplatin, this substitution places
the thiourea trans to an ammine ligand, whereas for trans-[Pt(NH3)2Cl2] the thiourea binds
trans to a chloride. The ammine of cisplatin is sufficiently labilized by the thiourea ligand
such that it can be displaced. The ammines of the trans isomer are never found in a position
trans to the thiourea ligand and therefore remain coordinated. The use of the Kurnakow test
in conjunction with HPLC provides a powerful and sensitive method to detect isomeric
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impurities.82,83 In contrast to cis- and trans-[Pt(NH3)2Cl2], the thiourea-coordinated
products exhibit significantly different retention times and contain stronger UV-vis
absorbance features, properties that make them amenable for HPLC analysis. NMR
spectroscopy provides another potential tool to distinguish between isomers. Unfortunately,
the 195Pt NMR chemical shifts of the cis and trans isomers are very similar, with δ = −2104
ppm for cisplatin and −2101 ppm for trans-[Pt(NH3)2Cl2)].84. The evaluation of 3-bond Pt–
H coupling constants (3JPtH) determined by 1H NMR spectroscopy, however, revealed that
these values are 8–14 Hz greater for the cis isomers of these complexes,85 indicating that the
magnitudes of these coupling constants can be used to distinguish the two isomers. A
potential limitation to this method is the need for a low-field NMR spectrometer in order to
minimize chemical-shift anisotropy effects of the 195Pt nucleus, which broaden resonances
and obscure coupling.
The discovery that trans-[Pt(NH3)2Cl2] lacks the biological activity of cisplatin influenced
the early structure-activity relationships derived for platinum-based anticancer
agents.28,86,87 In contradiction to these structure-activity relationships, which prescribe cis
geometry for activity, it was later discovered that some trans complexes of general formula
[PtCl2L2] are cytotoxic when L is an N-heterocycle like pyridine or thiazole.88–90 Several
methods have been described for the synthesis of these symmetric trans compounds from the
[PtCl4]2− ion. To prepare trans-[Pt(NH3)2Cl2], excess ammonia is added to the [PtCl4]2−
anion to generate the cationic complex, [Pt(NH3)4]2+. The [Pt(NH3)4]Cl2 salt forms
colorless aqueous solutions from which trans-[Pt(NH3)2Cl2] can be precipitated as a yellow
solid after the addition of hydrochloric acid (Scheme 3).57 This synthetic pathway also
exemplifies the trans effect principle. After treatment of [Pt(NH3)4]Cl2 with HCl, an
ammine ligand is replaced by a chloride, forming [Pt(NH3)3Cl]+. The trans effect of chloride
is greater than that of ammonia. Hence, the next incoming chloride ion preferentially
displaces the ammine trans to the coordinated chloride, selectively giving rise to the trans
isomer. This general scheme is applicable to other amine ligands and N-heterocycles as
well.90 Trans complexes can also be prepared directly from [PtL4]X2 compounds without
the use of hydrochloric acid. Upon heating [PtL4]X2 as a suspension in an organic solvent or
as a solid under vacuum, the outer-sphere halides substitute the inner-sphere amine or N-
heterocycle, exclusively generating the trans isomer.90–93 In an attempt to make trans-
[PtL2Cl2], where L is imidazole, [PtL4]Cl2 was treated with HCl. Instead of obtaining the
expected product, trans-[PtL2Cl2], only platinum(IV) complexes were obtained.61 The
reaction of [PtL4]Cl2 with excess Et4NCl in refluxing DMF ultimately gave the desired trans
complexes.61 Interestingly, for the analogous complex where L is pyrazole, trans-[PtL2Cl2]
could be obtained from [PtL4]Cl2 and HCl without any reported difficulties.94
As described in Section 1, leaving group ligands can have profound effects on the biological
properties of the resulting platinum complexes. The importance of this behavior is
exemplified by the clinically used drugs carboplatin and nedaplatin (Chart 1), which differ
from cisplatin only by substitution of the chloride leaving groups with chelating ligands. The
chloride ligands of complexes of general formula cis- and trans-[PtL2Cl2], where L is an
amine or N-heterocyclic ligand, can readily be replaced by other desired ligands. A number
of different synthetic routes are available for substitution of the halides with other ligands.
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For the synthesis of dicarboxylato species, these synthetic routes and their practical
applications have been reviewed in great detail.95 Here, we summarize these reactions
schemes and reiterate some practical aspects.
Typically, a water-soluble silver(I) salt, such as AgNO3, is allowed to react with a
suspension of the platinum(II) complex in water. Silver chloride or iodide is formed as a
white or yellow solid, respectively, and removed by filtration. The filtrate contains the
substitution-labile complex [PtL2(OH2)2]2+. The protonation state and charge on this cation
depend on the pH of the solution. At high pH, substitution-inert platinum(II) hydroxo
compounds form. These species readily oligomerize to form multinuclear platinum(II)
complexes containing bridging hydroxide ligands, which are similarly resistant to
conventional ligand substitution reactions.39,65,96 At slightly acidic pH, however, the aqua
ligands are readily displaced by other nucleophiles. Treatment of cis-[PtL2(OH2)2]2+ in
water with sodium salts of anionic nucleophiles, NaNu, forms the complexes cis-
[PtL2(Nu)2] (Scheme 4a). This reaction proceeds best when the resulting product is
insoluble in water and can then be isolated by filtration without the need to evaporate the
solution to dryness. In cases where the desired product is water soluble, contamination of the
final product with NaNO3 is a problem.97 In addition to preparing diamine dicarboxylato
platinum(II) complexes, this reaction has been used to synthesize platinum(II) diazido
complexes,98,99 which are precursors to photoreactive platinum(IV) prodrugs.100 The
platinum(II) dinitrato complexes, [PtL2(ONO2)2], can also be prepared independently and
isolated as solids, as evidenced in part by an early report of the X-ray crystal structure of cis-
[Pt(NH3)2(ONO2)2].101 An efficient synthesis of cis-[PtL2(ONO2)2] is accomplished by
treating cis-[PtL2I2] with AgNO3 in acetone.62,102 The reaction proceeds substantially faster
in acetone compared to water. Solid cis-[PtL2(ONO2)2] dissolves in water with heating to
form the diaqua species described above, which can then be used to install new leaving
group ligands.
An alternative reaction for preparing water-soluble complexes with modified leaving groups
utilizes a silver(I) salt of the desired new ligand. The silver(I) salts react directly with
cisplatin and related diaminedihalidoplatinum(II) complexes in water, yielding insoluble
AgX as the only byproduct (Scheme 4b). The resulting silver(I) halide can be removed by
filtration, leaving the soluble product to be recovered from the filtrate by evaporation of the
solvent. This strategy was employed for an optimized synthesis of radiolabeled 195mPt-
carboplatin.103 In cases where the silver(I) salt of a desired carboxylate ligand is not readily
available, a one-pot strategy can be employed, in which the diaminedihalidoplatinum(II)
complex, Ag2CO3, and the carboxylic acid are mixed together.95 In another approach, the
sulfate salt of [PtL2(OH2)2]2+, generated by the reaction of Ag2SO4 with [PtL2X2] in water,
is used in conjunction with Ba(II) salts of the carboxylates, usually formed in situ from
Ba(OH)2, to synthesize the desired platinum(II) carboxylate (Scheme 4c).97,104,105 The
byproduct of this reaction, insoluble BaSO4, can be easily removed by filtration. This
reaction has been used to attach β-diketonate106 and sulfonate107 ligands to platinum(II).
Another synthetic approach, which has not found widespread use, requires a platinum(II)
oxalate complex and the calcium salt of a ligand. The mixture of these two species generates
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insoluble calcium(II) oxalate and the target complex, the latter remaining in solution
(Scheme 4d).107
Various other interesting leaving groups have also been attached to platinum to generate
anticancer drug candidates. Platinum(II) diamine complexes with squarate,108 selenite,108
tellurate,109 ascorbate,110–112 and methyl sulfinyl carboxylate113,114 leaving groups have
been prepared using the protocols described above. Additionally, the complex [Pt(trans-1R,
2R-DACH)(B2O5H2)] with a chelating borate ligand was prepared from [Pt(trans-1R,2R-
DACH)(OH)2] and a mixture of boric acid and tetraborate in water.115 These novel
complexes demonstrate the synthetic versatility of the methods described above for
preparing new platinum compounds with different leaving group ligands, some of which
may have therapeutic potential.
2.2. Synthesis of cis- and trans-[PtLL'X2], Complexes with Mixed Am(m)ine Ligands
Platinum(II) complexes that bear two different amine or N-heterocyclic ligands have gained
importance in recent years as a new class of anticancer agents. The complexes cis-[Pt(NH3)
(2-picoline)Cl2] (picoplatin)116,117 and cis-[Pt(NH3)(cyclopentylamine)
(hydroxybutanedioato)] (cycloplatam)118 (Chart 2), for example, have undergone clinical
trials.23cis-[Pt(NH3)(cyclohexylamine)Cl2] (JM-118) (Chart 2), an active metabolite of the
clinically investigated platinum(IV) complex satraplatin,119,120 is another member of this
class of compounds. Trans platinum complexes of mixed amine or N-heterocyclic ligands
are also of importance. Some members of these “trans planar amine” (TPA) class of
compounds having the general formula trans-[Pt(NH3)LX2], where L is an N-heterocycle,
exhibit potent anticancer activity and are not cross-resistant with cisplatin.121 Moreover,
they serve as precursors for the preparation of phototoxic platinum(IV) diazido
complexes.98,122
The most straightforward synthetic route to mixed amine platinum(II) complexes with cis
stereochemistry involves the use of the [PtLCl3]− anion as an intermediate. Treating this ion
with another amine or N-heterocycle, L', is expected to yield the complex cis-[PtLL'X2]. A
limitation to this approach, however, is the difficulty in preparing
am(m)inetrichloridoplatinate(II) ions. Initial reports of the syntheses of K[Pt(NH3)Cl3]
(Cossa's salt) appeared over a century ago.123,124 Since then, researchers have focused on
finding straightforward, high yielding protocols for obtaining this and related ions. The
treatment of K2PtCl4 with one equiv of L more readily generates 0.5 equiv of the highly
insoluble cis-[PtL2Cl2] complex rather than the soluble salt K[PtLCl3]. An early, inefficient
preparation of K[Pt(NH3)Cl3] involved treatment of cisplatin with hydrochloric acid in the
presence of a catalytic amount of Pt metal at elevated temperatures.125 After removing
unreacted cisplatin and Pt metal by filtration, the [Pt(NH3)4]2+ cation was added to
precipitate the salt [Pt(NH3)4][Pt(NH3)Cl3]2. This salt was then treated with K2PtCl4, giving
insoluble Magnus' salt, [Pt(NH3)4][PtCl4], and Cossa's salt, K[Pt(NH3)Cl3], in the filtrate. A
typical yield was not reported for this method, but the large quantity of undesired platinum-
containing byproducts makes this approach expensive and undesirable. The reaction was
later optimized to obtain Cossa's salt in 60% yield from cisplatin.126 In this case, the salt
was isolated by anion-exchange chromatography and therefore did not require formation of
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the platinum double salts. With careful control of temperature and reaction time, the
ammonium salt of [Pt(NH3)Cl3]− was reportedly isolated in 90% yield, also by the action of
hydrochloric acid on cisplatin, but in the absence of a Pt metal catalyst.127
An alternative, more commonly used route for the preparation of the [Pt(NH3)Cl3]− anion
employs N,N-dimethylacetamide (DMA) as the solvent.128,129 At high temperatures (100
°C) with a stream of nitrogen gas bubbling through the DMA solution, the direct reaction
between an excess amount of tetraethylammonium chloride and cisplatin affords the desired
anion, which can be subsequently precipitated from an aqueous solution as the PPh4+ salt.128
The use of other cis-[PtL2Cl2] complexes as starting materials in this reaction generally
affords the corresponding [PtLCl3]− ions. This transformation, however, is only successful if
the leaving amine ligand is sufficiently volatile, driving the reaction by evaporation of the
amine. Because of this limitation, the anion [Pt(cyclohexylamine)Cl3]− could not be
prepared by this method.128 The high temperatures employed, which result in the eventual
decomposition of cisplatin to insoluble platinum black, restrict the overall yield and
efficiency of the reaction. The introduction of substoichiometric amounts of NH4Cl (0.25
mol%) prevents formation of platinum black (Scheme 5).130 The reported yield in this case
was 58%, but unreacted cisplatin could be recovered for later use.130 Water-soluble forms of
the [Pt(NH3)Cl3]− ion as either its sodium or potassium salt can be isolated using an ion-
exchange resin,129,130 or metathesis with either KPF6131 or NaBPh4.132 An HPLC method
was described recently to assess the purity of the potassium salt.133 To prepare the
analogous anions where L is an N-heterocycle instead of an amine, direct reaction between
K2PtCl4 and one equiv of L in DMF at 75 °C can be used. This reaction also produces some
of the disubstituted neutral product cis-[PtL2Cl2].134,135 The amount of this undesired
species formed depends on the steric bulk of the incoming heterocycle.135 For example,
much higher yields of the anion were afforded with 2,4-lutidine than with pyridine.
Presumably, the steric properties of the ortho methyl groups of 2,4-lutidine disfavor
simultaneous coordination of two such ligands to a single platinum center. The use of steric
effects to synthesize of [PtLCl3]− directly from K2PtCl4 in water, where L is an aliphatic
amine, has also been described.136 The sterically crowded amines, isopropyl and tert-butyl
amine, substantially retard the formation of cis-[PtL2Cl2], enabling isolation of K[PtLCl3] in
16–36% yields.136 For either reaction, the desired soluble anion can be separated from the
insoluble disubstituted complex by extraction into water.
The [PtLCl3]− ions are suitable precursors for the synthesis of mixed ligand complexes of
the type cis-[PtLL'X2]. The reaction between L' and [PtLCl3]− in water or DMF gives the
mixed amine complex with the expected cis stereochemistry.128,137–139 Under these
conditions, however, a small amount of cis-[PtL'2Cl2] can also be formed, presumably
arising from [PtCl4]2− impurities in the starting material.129 By analogy to Dhara's method
for the synthesis of cisplatin,60 the preparation of cis mixed amine complexes was improved
by first treating the [PtLCl2]− anion with 2 equiv of NaI or KI in water (Scheme 5).126
Multinuclear NMR spectroscopic studies verified that the addition of two equiv of iodide,
when L = NH3, forms primarily the trans-[PtI2Cl(NH3)]− ion, resulting from substitution of
two chloride ligands.140 The large trans effect of the iodide favors the amine substitution
reaction. The addition of an amine, L, to trans-[PtI2Cl(NH3)]− readily yields the mixed
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halide species [PtL(NH3)ClI], where L is trans to the iodide ligand. In this case, some
impurity resulting from [PtCl4]2− is present in the form of cis-[PtL'2I2]. This impurity,
however, can be readily removed from the desired product by its dissolution in acetone.129
The mixed halide intermediate can then be converted to the dichloride by removal of the
iodide ligand with Ag+ and addition of Cl− to the resulting platinum aqua complex (Scheme
5). In the case where both L and L' are quinoline derivatives, the direct reaction of [PtLCl3]−
and L' in mixed aqueous and organic solvent directly afforded the desired compound in its
pure form without the need to proceed through the mixed halide species.141
The other commonly used route for preparing mixed cis amine platinum(II) complexes
utilizes iodido-bridged dimers, [PtLI(μ-I)]2, as intermediates. The reaction of cis-[PtL2I2]
with perchloric acid forms these species, which are generally insoluble and brown in color
(Scheme 6).142 The scope of this reaction extends to a range of aliphatic143 and aromatic
amines,144 and N-heterocycles.145 For sterically hindered amines, such as tert-butyl amine,
the analogous iodido-bridged dimers form directly upon reaction with K2PtI4; formation of
the expected product, cis-[PtL2I2], does not occur, presumably owing to the large steric
hindrance of the bulky amine ligands.143 The perchloric acid serves to remove an amine
ligand from cis-[PtL2I2] by protonolysis. The vacant coordination site on the platinum(II)
center is then filled by an iodide ligand from another complex. Because both the starting
material and products are poorly soluble in water, the reaction can take an exceedingly long
time to reach completion; for cyclopropyl amine, a reaction time of three weeks was
necessary to achieve full conversion.143 Furthermore, the lack of solubility of both species
makes it difficult to gauge the extent of the reaction. For reactions that have not gone to
completion, the final product may be contaminated by starting material. The iodido-bridged
dimers exist in two isomeric forms, syn and anti (Scheme 6), depending on the disposition of
the two amine ligands about the Pt–Pt vector. Solution NMR spectra display resonances
from both isomers, but in the solid-state only anti isomers have been observed by X-ray
crystallography.143,146
Although several recent publications have reported that some of these iodido-bridged dimers
exhibit anticancer activity,147,148 their primary use is to prepare cis mixed amine complexes.
In this context, it should be noted that these iodido-bridged dimers can also serve as
precursors for the [PtLCl3]− 3 anion discussed above. Treatment of [PtLI(μ-I)]2 with excess
AgNO3 in water, followed by the addition of excess KCl, provides another route to the
[PtLCl3]− ion.149 More useful, however, is the direct reaction of these dimers with another
amine or N-heterocycle to form the mononuclear mixed amine complexes, cis-[PtLL'I2]
(Scheme 6).131,142 2 Despite the presence of both anti and syn isomers in the iodido-bridged
dimer starting material, only cis-[PtL2I2] is obtained from this reaction. The iodide ligands
can be exchanged for other halides using an appropriate silver (I) salt as described above.
Analogous chlorido-bridged dimers can be synthesized by the photolysis of trans-
[Pt(ethylene)LCl2].150 Cleavage of these chlorido-bridged dimers with another amine
ligand, however, leads to formation of both the trans and cis isomers of the mixed amine
complex,150 rendering this procedure less useful.
When a bidentate oxygen ligand is desired as the leaving group instead of monodentate
halides, a different synthetic route can be used to access the mixed amine complex. The first
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step in this pathway requires the synthesis of cis-[Pt(DMSO)2(O2Chel)], where O2 Chel is a
typically anionic chelating ligand with oxygen donor atoms. This intermediate is prepared
by the reaction of cis-[Pt(DMSO)2Cl2], which itself is obtained from commercially available
K2PtCl4 and DMSO,151 and the disilver salt of the chelating ligand in water (Scheme 7).152
The first DMSO ligand of cis-[Pt(DMSO)2(O2Chel)] can be substituted by an amine L at 40
°C in water to form isolable complexes of the type cis-[PtL(DMSO)(O2Chel)]. The addition
of a different amine, L', to this complex at higher temperatures (100 °C) in water enables
substitution of the second DMSO ligand to afford the mixed amine complex cis-
[PtLL'(O2Chel)] (Scheme 7).152 The difficulty in removing the second DMSO ligand is
emphasized by the fact that even the use of chelating diamine ligands requires heating to 100
°C to enforce bidentate coordination. For bidentate N-heterocycles like 2,2'-bipyridine,
lower temperatures (refluxing methanol) can be used to substitute both DMSO ligands.153
The concentrations of the reactants are also important because, when high concentrations of
chelating diamine ligands are used, both the DMSO ligands and oxygen chelate get
displaced, forming [Pt(L2)2]2+.154 Despite the apparent utility of this method, it has not been
widely applied.95,155–157
The processes for preparing mixed amine complexes with trans stereochemistry are more
straightforward than those discussed above for cis complexes. These compounds, having the
general formula trans-[PtLL'Cl2], are of interest because many of them display in vitro
anticancer activity superior to that of cisplatin, despite their trans stereochemistry.158–163
Additionally, they exhibit no cross-resistance with cisplatin.158,159,161 Their preparation
begins with the complex cis-[PtL2Cl2], the synthesis of which has been described earlier.
The addition of greater than two equiv of L' to a suspension of this complex in boiling water
typically gives rise to a colorless solution containing the salt, cis-[PtL2L'2]Cl2 (Scheme 8).
The solubility and color can vary slightly, depending on the hydrophobicity and electronic
properties of the amine or N-heterocycle ligands. Addition of concentrated hydrochloric acid
to this salt at elevated temperatures leads to substitution of one L and one L' ligand by
chloride, forming trans-[PtLL'Cl2] (Scheme 8).158 The stereochemistry of the product is
dictated by the kinetic trans effect. The first chloride substitution can yield either of the
intermediates, [PtL2L'Cl] or [PtLL'2Cl2]. The larger trans effect of chloride compared to
those of amines or N-heterocycles ensures that the second chloride substitutes trans to the
first chloride. Further substitution to form [PtLCl3]2− is impeded by the low solubility of
trans-[PtLL'Cl2], which precipitates from solution as a yellow solid immediately upon its
formation.
2.3. Synthesis of Monofunctional Platinum(II) Complexes
Platinum(II) complexes containing only one substitution-labile ligand are designated as
`monofunctional' in contrast to cisplatin and carboplatin, both of which contain two
substitution-labile coordination sites and are referred to as `bifunctional.' Among the first
monofunctional platinum(II) complexes investigated for their potential anticancer activity
were [Pt(dien)Cl]Cl (dien = diethylenetriamine) and [Pt(NH3)3Cl]Cl. The observation that
these two complexes are inactive helped establish the traditional structure-activity
relationships for platinum therapeutics, which state that, among other requirements, charge
neutrality and bifunctionality are necessary for activity.28,164 Despite their lack of anticancer
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properties, these two monofunctional complexes have been useful in modeling the reactions
of platinum complexes with biologically relevant nucleophiles because the presence of only
one exchangeable ligand site simplifies interpretation of the results.165–168
Optimized synthetic routes to these salts are available.169,170 The synthesis of
[Pt(NH3)3Cl]Cl commences by treatment of trans-[Pt(NH3)2Cl2] with one equiv of KI to
form the mixed halide complex, trans-[Pt(NH3)2ICl]. The addition of 1 equiv of AgNO3 in
water selectively precipitates AgI and gives trans-[Pt(NH3)2Cl(OH2)](NO3). Aqueous
ammonia readily replaces the labile aqua ligand, yielding [Pt(NH3)3Cl]Cl as a colorless to
pale yellow solid after precipitation from the aqueous solution with a mixture of ethanol and
diethyl ether (Scheme 9).169 The aqua intermediate, trans-[Pt(NH3)2Cl(OH2)](NO3), could
also conceivably used as a synthon for complexes of the general type, trans-[Pt(NH3)2LCl]
(NO3). The optimized preparation of [Pt(dien)Cl]Cl utilizes the reaction of either cis/trans-
[PtCl (SMe 171 or cis-[Pt(DMSO)2Cl2151 with dien in refluxing methanol. Isolation of
[Pt(dien)Cl]Cl as a white solid in yields of >90% is accomplished by the addition of either
CHCl3 or CH2Cl2 to the resulting methanolic reaction mixture.170
More recently, a number of monofunctional platinum(II) complexes have been discovered
that break the traditional structure-activity relationships by exhibiting anticancer
properties.172–176 The most thoroughly investigated members of this class are complexes of
general formula cis-[PtL2L'Cl]+, where L is a monodentate or bidentate amine and L' is
either an N-heterocycle,172 a sulfoxide,173,177,178 or a thiourea derivative (Chart 3).179
For the sulfoxide and thiourea complexes, chelating diamines are used exclusively because
the strong trans effect of these ligands labilizes monodentate amines, leading to their
dissociation. Although we define the sulfoxide compounds, cis-[Pt(L2)(RR'SO)Cl]+, as
monofunctional because of the presence of only one labile Pt–Cl bond, these complexes
form bifunctional DNA-adducts.180 Rapid substitution of the chloride for water or
nucleobases is followed by the slow substitution of the sulfoxide ligand. The kinetics of the
sulfoxide substitution reaction are effectively modulated by its steric bulk.173,177,180 The
synthesis of these complexes proceeds either by the addition of the chelating amine ligand to
cis-[PtCl2(RR'SO)2] or the addition of one equiv of sulfoxide to cis-[Pt(L2)Cl2] (Scheme
10). The latter reaction pathway is the preferred route; the use of cis-[PtCl2(RR'SO)2] as the
starting material in the former pathway gives variable amounts of cis-[Pt(L2)Cl2] as an
undesired byproduct.173
Complexes of the type cis-[Pt(NH3)2+, where L is an N-heterocycle, have attracted
significant attention since the initial discovery of their antitumor properties in 1989.172 In
contrast to the sulfoxide complexes discussed above, these cations bind to DNA and
nucleobases in a monofunctional manner with no indication of ammonia or N-heterocycle
loss to form bifunctional adducts.181 Although the monofunctional lesions do not
significantly bend DNA,26,182 they still manage to effectively destabilize the structure of the
double helix183–185 and impede DNA replication186 and transcription.26,187 The
characteristic monofunctional DNA adducts may be responsible for the different spectrum of
activity observed for these compounds in comparison to those for clinically used
bifunctional platinum drugs.188 A number of derivatives of cis-[Pt(NH3)2+ have been
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synthesized, with L being a wide range of different N-heterocycles. These N-heterocycles
include derivatives of pyridine with different substituents172 and fused aromatic rings,189
pyrimidines,190 a fluorescently labeled pyridine,191 steroid functionalized pyridines,192,193
imidazothiazoles,194 9-aminoacridine,195 the antimalarial drug chloroquine,195 ethidium,196
the anticancer drug 5-fluorouracil,197 and several antiviral agents.198,199 Of these drug
candidates, the complex utilizing phenanthridine as its N-heterocyclic ligand, termed
phenanthriplatin, exhibits in vitro cytotoxicity greater than that of cisplatin across a wide
range of cell lines.189 As phenanthriplatin illustrates, the judicious choice of the N-
heterocycle can give rise to very potent monofunctional complexes.
The synthesis of monofunctional complexes can be accomplished by stirring a mixture of
cisplatin and one equiv of the N-heterocycle in water at 50–60 °C for several days.172 This
reaction proceeds by direct substitution of the chloride ligand by the N-heterocycle. This
method, however, typically gives low yields of impure compounds. The major impurity is
the disubstituted species, cis-[Pt(NH3)2L2]Cl2, which arises from substitution of both
chloride ligands. Pretreatment of cisplatin with one equiv of AgNO3 in water to generate the
reactive monoaqua complex, cis-[Pt(NH3)2]+, followed by the addition of another ligand has
also been reported.190 This method gave rise to a substantial portion of unreacted cisplatin
and unidentified byproducts. The reaction mixture containing one equiv AgNO3 and
cisplatin in water has been analyzed by 195Pt NMR spectroscopy. The monoaqua complex,
cis-[Pt(NH3)2Cl(OH2)]+, comprises 57% of the total platinum in solution, whereas the
diaqua complex, cis-[Pt(NH3)2(OH2)2]2+, and unreacted cisplatin account for 39 and 4%,
respectively. The large quantity of the diaqua complex should lead to the formation of an
equally large proportion of the undesired disubstituted complex. Treating cisplatin with one
equiv of AgNO3 in DMF, however, gives a much more favorable product distribution; 79–
86% of the total platinum is in the monosolvated form cis-[Pt(NH3)2Cl(solv)], where “solv”
is either DMF or nitrate, whereas only 9% and 9–12% of the platinum comprises doubly
solvated species and unreacted cisplatin, respectively.172,195 The preferred synthetic route to
monofunctional complexes, therefore, involves the reaction of cisplatin with one equiv of
AgNO3 in DMF followed by the addition of the N-heterocyclic ligand (Scheme 11).172,200
Care must be taken to purify the final monofunctional product from unreacted cisplatin and
disubstituted byproducts. Because cisplatin is not soluble in methanol, it can be removed by
filtration after dissolving the crude product in this solvent. A final recrystallization step from
either dilute HCl or methanol is necessary to separate the monofunctional complex from
disubstituted byproducts. The mononitrato species, cis-[Pt(NH3)2Cl(NO3)], has reportedly
been isolated as a solid by evaporation of an aqueous solution containing a 1:1 mixture of
cisplatin and AgNO3.199 This complex was then used as a precursor for new monofunctional
complexes. Only CHN analyses were presented as characterization for cis-
[Pt(NH3)2Cl(NO3)]; it is most likely that the isolated solid comprised the mixture of species
found in solution by 195Pt NMR spectroscopic studies, as discussed above.
Another important class of monofunctional platinum anticancer agents contains complexes
of the general formula cis-[Pt(L2)Cl(tu)]+, where L2 is a chelating diamine ligand and tu is a
derivative of thiourea, coordinated through the sulfur atom (Chart 3, right side).201,202
Although the first generation analogues of these complexes with underivatized thiourea
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ligands exhibit only poor to moderate in vitro cytotoxicity,203 the second generation
compounds with acridine-functionalized thioureas are typically more cytotoxic than
cisplatin.174,204,205 These Pt-acridinylthiourea, or PT-ACRAMTU, conjugates form hybrid
DNA adducts;206 the Pt center binds preferentially to N7 of guanine bases and the acridine
intercalates between base pairs. Several dichloridoplatinum(II) complexes tethered to
acridine through a modified ethylenediamine ligand, first reported in the late 1980s, also
exhibit dual intercalation and covalent DNA-binding modes.74,75,207 The covalent adducts
of these complexes, however, are bifunctional as opposed to the monofunctional adducts
formed by PT-ACRAMTU compounds. In contrast to the monofunctional sulfoxide
complexes discussed above, the thiourea ligand does not get displaced by nucleobases and
therefore only monofunctional covalent DNA adducts are formed.203 The unique hybrid
DNA-binding motif of these complexes gives rise to a profile of activity in a wide range of
cancer cells substantially different from those of cisplatin and related platinum anticancer
drugs.179 The synthesis of PT-ACRAMTU complexes follows a protocol similar to that used
for the monofunctional cis-diammine complexes. A 1:1 mixture of cis-[Pt(L2)Cl2] and
AgNO3 is stirred in DMF, and the filtrate is treated with one equiv of the thiourea ligand
(Scheme 12).208 This reaction fails when monodentate amine ligands are used; the addition
of thiourea induces full substitution of the monodentate amine ligands, forming
[Pt(tu)4]2+,208 consistent with the expected results of the Kurnakow test, as discussed above.
2.4. Platinum(II) Complexes Synthesized by Ligand-Based Reactivity
The synthetic strategies discussed in the previous sections all rely on ligand substitution
reactions at the platinum(II) center. Alternative synthetic pathways involve the use of outer-
sphere, ligand-based reactivity. These reactions are facilitated by the ability of transition
metal ions to activate coordinated ligands, making them more susceptible to certain
reactivity pathways that would otherwise be inaccessible to them in the unbound form. This
section covers several examples of these reactions that have been utilized to synthesize of
novel platinum anticancer drug candidates.
Iminoether complexes of platinum(II) of general formula [Pt(iminoether)2Cl2] display
potent anticancer activity both in vitro and in vivo. As for traditional platinum anticancer
agents, this activity is proposed to arise from DNA binding.209 For the trans isomers,
monofunctional adducts210,211 and protein-DNA cross-links212 are invoked as the
predominant cytotoxic lesions. The trans isomers tested initially proved to be more active
than their cis congeners,213 although some recent studies have reported the opposite
observation for new members of this class of compounds.214,215 The cis and trans structure-
activity relationships for these compounds, therefore, depend on the exact chemical nature
of the iminoether ligand. In addition to the stereochemistry at the square-planar platinum
center, the iminoether ligands can exist in either E or Z configuration, depending on the
orientation of the substituents about the C–N double bond. As a result, there are six isomers
for [Pt(iminoether)2Cl2] complexes, neglecting rotational isomers involving hindered
rotation about the Pt–N bond vector (Chart 4). For both cis and trans isomers, the
stereochemistry of the ligand has a substantial effect on the biological activity of the
complex.213,216 Therefore, precise synthetic control over the total stereochemistry of the
final complex is important for further biological applications.
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The nitrile complexes, cis- and trans-[PtCl2(NCR)2], are precursors for preparing cis- and
trans-[PtCl2(iminoether)2] complexes. The reaction of cis- or trans-[PtCl2(NCR)2] in
alcohols217 or alcohol-dichloromethane mixtures218 with a catalytic amount of KOH affords
the iminoether complexes by nucleophilic attack of the alkoxide on the coordinated nitrile
ligand (Scheme 13). Formation of the iminoether occurs with retention of the starting
stereochemistry of the platinum complex, but generally a mixture of E and Z ligand-based
isomers is obtained. Formation of the Z iminoether is kinetically preferred; isomerization to
the E isomer occurs in the presence of catalytic amounts of base, which is present under the
reaction conditions.219 Carrying out the reaction at low temperature (0 °C) also significantly
impedes isomerization to the E isomer, giving predominantly Z isomers.220 The ZZ, EZ, and
EE isomers can be separated on the basis of solubility differences by fractional
crystallization or silica gel column chromatography.219 Recently, the reaction of cis- and
trans-[PtCl2(NCR)2] with thiols was disclosed.221 Utilizing n-BuLi as the base and THF as
the solvent at rt, both cis and trans complexes afford bis(imino thioether) platinum(II)
compounds. The reaction proceeds cleanly, forming only imino thioether ligands with E
configurations.221
Mixed iminoether-ammine platinum(II) complexes of formula [PtCl2(NH3)(iminoether)]
also exhibit in vitro and in vivo anticancer activity.220,222 These complexes are prepared
from mixed ammine-nitrile complexes by the attack of an alkoxide on the coordinated nitrile
ligand under conditions similar to those employed for the bis(iminoether) complexes
described above. The synthetic protocols for the precursor complexes, cis- and trans-
[PtCl2(NH3)(NCR)], are similar to those described for mixed amine platinum(II) complexes
described above. To prepare trans-[PtCl2(NH3)(NCR)], cis-[Pt(NH3)2I2] is treated with two
equiv of AgNO3 in water to form the diaqua complex, from which cis-[Pt(NH3)2(NCR)2]
can be formed by addition of a large excess of nitrile at 70 °C. Excess aqueous KI displaces
two ligands; the large trans effect of iodide enforces trans stereochemistry in the final
product, trans-[PtI2(NH3)(NCR)]. The iodide ligands can be replaced by chlorides via
sequential treatment with AgNO3 and KCl. The synthesis of cis-[PtCl2(NH3)(NCR)] is
accomplished more simply by action of a large excess of nitrile on Cossa's salt,
K[Pt(NH3)Cl3].220
In addition to alcohols, alkoxides, and thiols, platinum(II) nitriles are also activated for
nucleophilic attack by amines to form amidine complexes. Amidine complexes of formula
cis- and trans-[PtCl2(amidine)2], cis- and trans-[PtCl2(NH3)(amidine)], and trans-
[Pt(amine)2(amidine)2]Cl2 have been investigated for anticancer potential, both in vitro and
in vivo.223–228 Like their iminoether analogues, these complexes generally show good
activity in both cisplatin-sensitive and -resistant cell lines. Additionally, both metal- (cis or
trans) and ligand-based (EE, EZ, or ZZ) stereoisomers are possible, as for the related
iminoether complexes. The syntheses of cis- and trans-[PtCl2(amidine)2], like those for the
analogous iminoether complexes, begin with cis- and trans-[PtCl2(NCR)2]. Low
temperature reactions (−10 °C) of the bis(acetonitrile) complexes with secondary or primary
amines in CH2Cl2 affords the amidine complexes (Scheme 14).229 For the cis isomer, five
equiv of the amine are required, whereas for the trans isomer 50 equiv of amine are required
for complete conversion to the diamidine product.230 The metal stereochemistry is initially
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retained in both cases, but in pure water these complexes isomerize, forming an equilibrium
mixture of cis and trans species.231 This isomerization is prevented in the presence of 100
mM NaCl.231 The stereochemical outcome of the amidine ligand (E vs Z) appears to be
dictated by the nature of the coordinated nitrile ligand and the nucleophilic amine. In the
reaction with the bis(acetonitrile) or bis(benzylcyanide) platinum complexes, primary
amines selectively give ZZ isomers and secondary amines give EE isomers.225,232 When the
coordinated nitrile is benzonitrile, a mixture of EE and ZZ isomers is obtained.233
Preparative TLC can be used to separate and isolate some of these isomers.223
The action of ammonia on both cis- and trans-[PtCl2(NCR)2] has also been
investigated.224,234 For cis dinitrile complexes, addition of aqueous ammonia in THF
affords the expected diamidine species.224 When gaseous ammonia is bubbled through a
CH2Cl2 solution of the trans dinitrile complex at −10 °C, the major product is trans-
[PtCl(NH3)(amidine)2]Cl, which results from substitution of a chloride ligand by ammonia
in addition to the expected attack on the coordinated nitrile.234 This complex is also the
major product when the trans dinitrile complex is treated with aqueous ammonia in THF.224
At room temperature and with 24 h reaction times, both chlorides of trans-[PtCl2(NCR)2]
can be substituted by aliphatic amines or ammonia to form the salts, trans-
[Pt(amine)2(amidine)2]Cl2 (Scheme 14)235, which also exhibit anticancer activity.227 The
greater tendency of the trans dinitrile complex to lose its chloride ligands in comparison to
that of the cis is proposed to be a consequence of the greater solubility of the intermediate
diamidine complex, trans-[PtCl2(amidine)2], which makes it susceptible to further reactivity
with the nucleophilic amines. For the cis complex, the diamidine complex precipitates from
solution, thus impeding further substitution reactions.
Using the abovementioned amidine-forming reactions, new analogues of the monofunctional
PT-ACRAMTU complexes, discussed above, were prepared.236 These complexes have the
general formula, cis-[PtCl(L2)(amidine)](NO3), where L2 is either two ammine ligands or a
chelating diamine, and the amidine ligand is tethered to an intercalating acridine unit. These
complexes display excellent activity against non-small cell lung cancer (NSCLC) cell lines,
having no cross-resistance to cisplatin.236 Furthermore, compared to first generation
thiourea analogues, these amidine complexes react less readily with cysteine sulfur,237 yet
bind more rapidly to DNA.238 By comparison to cisplatin, these complexes display a
significantly larger degree of intracellular accumulation and DNA platination.239 The
syntheses are accomplished by first treating cis-[PtL2(NCR)Cl]Cl with 1 equiv of AgNO3 to
exchange the outer-sphere chloride with a nitrate counterion, followed by addition of an
acridinyl amine to a DMF solution of the complex at −10 °C (Scheme 15).236 Acidic
workup with HNO3 yields the product in its protonated form. The low temperature
conditions employed during addition of the amine are presumably necessary to prevent it
from displacing the chloride ligand. The mononitrile precursor complex, cis-
[PtL2(NCR)Cl]Cl, is synthesized by refluxing a mixture of cis-[PtL2Cl2] and excess nitrile
in dilute HCl (Scheme 15).236,240 This straightforward, amidine-forming reaction has
recently been applied to screen combinatorially a number of new platinum complexes that
differ in the starting nitrile ligand and the acridinyl amine.241 The method was used to
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delineate some structure-activity relationships for this new class of platinum anticancer
complexes.241
In addition to nitriles, amines and ammonia are also activated for novel reactivity pathways
when coordinated to platinum. Such ligands can engage in condensation reactions to form
coordinated imines or iminates. For example, reactions of [Pt(NH3)6]4+ and [Pt(en)3]4+ with
acetylacetone afford β-diketiminate complexes.242,243 Additionally, both cis- and trans-
[Pt(NH3)2Cl2] react with 2-pyrdinecarboxaldehyde to form [Pt(pmpa)Cl], where pmpa = N-
(2-picolyl)picolinamide), presumably by condensation of the coordinated NH3 group with
the aldehyde (Scheme 16).244 Ammine insertion into a carbon-carbon double bond of the
axial ligand of a platinum(IV) complex has also been observed.245 Acetonimine complexes
of platinum(II), cis and trans-[PtX2(acetonimine)2] where X = Cl or I, were synthesized by
the reaction of cis and trans-[Pt(NH3)2X2] with acetone in the presence of KOH (Scheme
16).246 These complexes are of therapeutic interest because they display good in vitro
anticancer activity against a panel of human cancer cell lines without exhibiting cross-
resistance to cisplatin.246cis- and trans-[Pt(NH3)2Cl2] react more slowly with acetone than
their corresponding iodide analogues, with complexes of cis stereochemistry being more
reactive than the trans complexes. Based on these observations, the ligand trans to the
ammines is proposed to modulate the condensation reactivity, which occurs first by
deprotonation of the ammine to form a nucleophilic amido ligand. Higher trans effect
ligands lower the ammine pKa by stabilizing the anionic amido ligand. Another route to
bis(acetonimine) platinum(II) complexes was also reported; direct ligand substitution
reaction of [PtL2Cl2] (L in this case is a phosphine) by [Ag(acetonimine)2]ClO4 affords such
species.247
Ligand-based reactivity does not necessarily require activation by platinum coordination. If
the ligand has a functional group that is not in direct interaction with the platinum ion, this
functional group can display its typical reactivity, provided that the reaction conditions or
byproducts do not lead to decomposition of, or ligand dissociation from, the platinum
complex. The platinum(II) complexes [Pt(edma)Cl2] and [Pt(edda)Cl2], where edma =
ethylenediaminemonoacetic acid and edda = ethylenediamine-N,N'-diacetic acid, can engage
in reactions associated with their free carboxylic acid groups (Scheme 17). The reaction of
[Pt(edma)Cl2] with thionyl chloride in methanol converts the acid to a methoxy ester group,
presumably through an intermediate acid chloride.248 Furthermore, the carboxylic acids of
both [Pt(edma)Cl2] and [Pt(edda)Cl2] can be converted to amides after activation with 1,1'-
carbonyldiimidazole (CDI) and treatment with an amine.249,250 In both cases, the platinum
coordination sphere remains unaffected. Platinum(II) complexes of a chelating diamine
ligand having a pendant azide have also been synthesized.251 The azide functional group
was employed for a Cu(I)-catalyzed click reaction with terminal alkynes. This chemistry
was used to attach a number of different groups to the platinum complex (Scheme 17).
Notably, the coordination sphere of the platinum(II) core remained intact in the presence of
the Cu(I) catalyst.251 Platinum(II) complexes with thiol-reactive maleimide derivatives
attached to both the non-leaving252 and leaving group ligands253 were prepared. As
expected, the maleimide moiety readily reacted with thiols. This reaction was used to link
carboplatin derivatives to human serum albumin for improved tumor delivery.253
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3. Synthesis of Platinum(IV) Anticancer Complexes
Several platinum(IV) complexes have undergone clinical trials, but to date none has been
approved for use in the USA. Examples include iproplatin, tetraplatin, and satraplatin (Chart
5).23 An advantage of platinum(IV) complexes over their platinum(II) analogues is their six-
coordinate octahedral coordination geometry. The introduction of two additional ligands
allows for further tuning of the properties and confers the ability to attach functional or
targeting groups. Moreover, being complexes of d6 octahedral metal ions, platinum(IV)
compounds are substantially more inert than those of platinum(II). Thus, undesirable side
reactions with proteins or intracellular thiols can generally be avoided using platinum(IV)
complexes. The kinetic inertness of satraplatin is most likely the reason why it could be
administered orally, in contrast to all other platinum drugs, which are delivered
intravenously.
Because platinum(IV) complexes are inert, they usually undergo reduction to platinum(II)
before binding to their ultimate intracellular target, DNA.254,255 Reduction of platinum(IV)
occurs with loss of two ligands, giving a square-planar geometry for the platinum(II)
product. It has generally been assumed that the two ligands lost upon reduction are located
trans to each other and that both derive from positions along the axis orthogonal to the
original plane of four ligands. This longstanding notion has been challenged by number of
recent studies, which show that the composition of the reduced platinum(II) products
depends on the nature of the reducing agent.256–259 Furthermore, the kinetics of intracellular
platinum(IV) reduction depend both on the cell type260 and the ligands that define the
coordination sphere of the complex.261 The ability to rationally design new platinum(IV)
anticancer drug candidates using well defined synthetic chemistry is critical for discovering
new therapeutic agents and for further elucidating structure-activity relationships.262
3.1. Oxidation of Platinum(II)
A common synthetic route to complexes of platinum(IV) proceeds via two-electron
oxidation of an appropriate platinum(II) precursor. For potential platinum(IV) anticancer
agents, the most widely used oxidizing agents are hydrogen peroxide263 and chlorine.264
These two molecules react with platinum(II) to give trans oxidative addition products
(Scheme 18). The equatorial ligands of the resulting platinum(IV) complex are generally
retained with the stereochemistry of the starting platinum(II) compound. For some diamine
dicarboxylato platinum(II) complexes, however, the action of chlorine leads to undesired
displacement of the carboxylate groups to form diaminetetrachloridoplatinum(IV)
compounds.265
Platinum(IV) dihydroxo compounds, obtained by oxidation of platinum(II) complexes in
water, are important starting materials for the synthesis of further derivatized platinum(IV)
compounds (vide infra). The treatment of a yellow-orange suspension of cisplatin in water
with 10–100 fold excess of H2O2 at 50 °C gives rise to a pale-yellow suspension comprising
cis,cis,trans-[Pt(NH3)2Cl2(OH)2].266 This reaction is general, proceeding equally well for
cis and trans platinum(II) isomers.267 When isolated directly from the mother liquor, this
complex crystallizes with a molecule of hydrogen peroxide that forms hydrogen bonds with
the hydroxo ligands.268 Hydrogen peroxide is also retained in the crystal lattice of the
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related complex, cis,cis,trans-[Pt(iPrNH2)2Cl2(OH)2] (iproplatin).269 The observation that
these complexes are able to cleave DNA270,271 is a consequence of hydrogen peroxide in the
lattice rather than the platinum(IV) complex. The hydrogen peroxide can be removed by
recrystallization from pure water.266,267 For the all trans isomer, trans,trans,trans-
[Pt(NH3)2Cl2(OH)2], which does not contain lattice-bound hydrogen peroxide,
recrystallization from water leads to isomerization, giving trans,cis,cis-
[Pt(NH3)2Cl2(OH)2].267 Diphenyl phosphate (DPP) can also be incorporated into the crystal
lattice of trans-platinum(IV) hydroxo compounds.272 In these crystals, the diphenyl
phosphate forms strong hydrogen bonds with the coordinated hydroxide or water ligands.272
The DPP adducts exhibit improved aqueous solubility. Thus, the use of an appropriate co-
crystallization agent may enhance the pharmacological properties of the complex. The
abovementioned results point to a large degree of complexity for the H2O2 oxidation of
anticancer platinum(II) complexes. Care should be taken to avoid co-crystallized molecules
which themselves might have biological activity. Additionally, isomerization may impede
purification attempts.
The mechanism of platinum(II) oxidation by hydrogen peroxide and chlorine has important
implications for the composition of the isolated products. Studies of hydrogen peroxide-
oxidation of platinum(II) complexes using 18O-labeled water revealed that only one of the
hydroxide ligands on the platinum(IV) complex originates from hydrogen peroxide; the
other comes from water.275 Recently, the oxidation of [Pt(cis-1,4-DACH)Cl2] by chlorine
gas was investigated in several different solvents.276 By NMR spectroscopy, an intermediate
corresponding to the addition of one solvent molecule and one chloride ligand, fac-
[Pt(cis-1,4-DACH)(solv)Cl3]+, was detected. The remaining outer-sphere chloride
counterion then substitutes for the labile solvent molecule, giving the expected tetrachlorido
species.276,277 Further support for this mechanism comes from the crystal structure of a
mixed trans-chloridoaqua complex obtained by the aqueous chlorine oxidation of a
platinum(II) oxazole complex.278 Some early studies report the observation of a transient
red or orange color upon oxidation of cisplatin or [Pt(en)Cl2] with chlorine.264,279 The color
then changes to the characteristic yellow of the tetrachlorido complexes.264,279 In our lab,
we observed similar behavior following the oxidation of cisplatin and related platinum(II)
complexes with hypervalent iodine reagents. The transient red color has been proposed to
arise from dinuclear metal-metal bonded platinum(III) complexes, some of which are also
red and readily form tetrachloridoplatinum(IV) complexes by disproportionation.280,281
These dinuclear intermediates probably only occur at high platinum concentrations.
The use of coordinating solvents enables isolation of mixed trans oxidative addition
products. For example, oxidation of platinum(II) in alcohols with H2O2 gives trans hydroxo-
alkoxo complexes (Scheme 18).273–275,282–284 An optimized protocol for the synthesis of
cisplatin analogues of these species, cis,cis,trans-[Pt(NH3)2Cl2(OH)(OR)], utilizes high
dilution conditions in neat alcohol and oxidation with 50% aqueous H2O2.274,284 The use of
50% rather than 30% H2O2 presumably minimizes the amount of water in solution, which
can compete with the alcohol for coordination to platinum. Addition of hydrogen peroxide
to a platinum(II) complex with a 9-fluorenylidenepropanedioate (fpd) ligand in refluxing
methanol afforded a complex with two axial methoxide ligands instead of the expected
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mixed hydroxo-methoxo complex.282 The formation and stability of the dimethoxo complex
is proposed to arise from an intramolecular stabilizing interaction between the methoxide
and fpd ligands,282 and therefore this reaction is probably not general for most platinum(II)
complexes. The use of ethyleneglycol as a solvent for the hydrogen peroxide-oxidation of
platinum(II) affords a trans hydroxo-ethyleneglycolato complex.283 The terminal alcohol
group of the ethyleneglycolate ligand can presumably be further functionalized by
electrophiles, but such reactions have not yet been investigated.
The hydrogen peroxide-oxidation of platinum(II) complexes in the presence of carboxylic
acids has also been explored. The oxidation of [Pt(CBDCA)(DPDA)] (DPDA = 2,2-
dimethyl-1,3-propanediamine) in acetic acid with hydrogen peroxide gave the unexpected
cis diacetate complex, cis-[Pt(CBDCA)(DPDA)(OAc)2].285 In contrast, the use of acetic
anhydride mixed with a small amount of acetic acid, formed by hydrolysis of the anhydride,
as a solvent selectively afforded the trans diacetate complex, trans-[Pt(CBDCA)(DPDA)
(OAc)2] (Scheme 19).285 The mechanistic details and reasons for the isomeric preferences
of these reaction products have not yet been elucidated. The oxidation of the platinum(II)
dihydroxo compound, [Pt(DPDA)(OH)2], with hydrogen peroxide in carboxylic acids at
room temperature gave an unexpected species of general formula and stereochemistry, fac-
[Pt(DPDA)(OH)(O2CR)3] (Scheme 19).286 In our lab, we also explored the oxidation of
cisplatin with hydrogen peroxide in neat formic acid. The major product obtained is the
diformate complex, cis,cis,trans-[Pt(NH3)2Cl2(O2CH)2] (Scheme 19).287
Recently, the oxidation of oxaliplatin with hydrogen peroxide in the presence of greater than
40 equiv of carboxylic acid in a minimum volume of THF was reported.288 The major
products observed were the monocarboxylato species, trans-[Pt(trans-1,2-DACH)(oxalate)-
(OH)(O2CCR)].288 When bromoacetic acid was used, however, a large quantity of the
dicarboxylato species was obtained.288 This observation was rationalized based on the lower
pKa of bromoacetic acid (2.9) compared to those of the other acids screened (≈ 4.8). With its
greater acidity, the bromoacetic acid can protonate the second hydroxo ligand and displace
it, as discussed below. Unlike hydrogen peroxide-oxidations carried out in alcohols where
one alkoxide and hydroxide are added, there is a greater tendency to add at two carboxylate
ligands when the oxidation is performed in organic acids. The species initially formed are
most likely mixed hydroxo-carboxylato complexes, analogous to the mixed chlorido-
solvento species observed in chlorine oxidations.276 The highly acidic conditions, not
present in alcohol solutions, lead to protonation and subsequent substitution of the hydroxide
ligand by a carboxylate, as discussed below. The relative pKa values of the hydroxo ligands
and carboxylic acids most likely dictate whether the major product will be the mono or
dicarboxylato complex. Another strategy to prepare mixed hydroxo-acetato complexes
employs a different oxidant and solvent mixture.261,288 Oxaliplatin and trans-[PtLL'Cl2]
complexes, suspended in a 1:1:1 mixture of DMF, CH2Cl2, and acetic acid, can be oxidized
with tert-butyl hydroperoxide (in decane) to afford trans-[Pt(trans-1,2-DACH)(oxalate)
(OH)(OAc)] and trans,trans,trans-[PtLL'Cl2(OH)-(OAc)].261,288 The use of entirely non-
aqueous solvent and peroxide for these reactions prevents formation of the dihydroxo
compound. These complexes can serve as precursors for the synthesis of mixed
dicarboxylato species.
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Oxidation with hydrogen peroxide can also be used to increase the denticity of a ligand.
Platinum(II) complexes with the formulas [Pt(edma)Cl2], [Pt(edda)Cl2], and [Pt(edta)Cl2]
contain one, two, and four uncoordinated carboxylic acid groups, respectively. Upon
oxidation of [Pt(edma)Cl2] with H2O2, the carboxylate coordinates and the ligand binds in a
facial, tridentate manner, forming fac-[Pt(edma)Cl2(OH)] (Scheme 20).248 Similarly, both
carboxylates of [Pt(edda)Cl2] coordinate upon oxidation with H2O2.248,289 For
[Pt(edta)Cl2], only two of the four free carboxylates bind upon oxidation.290 The remaining
two carboxylates can potentially be functionalized by standard amide-bond coupling
chemistry, as for the platinum(II) analogues described above. These ring-closing reactions
provide a general synthetic route to stable platinum(IV) complexes with multidentate
ligands. The design of ligands for platinum(II) complexes with strategically placed donors
can facilitate such reactions upon oxidation.
Apart from chlorine and hydrogen peroxide, few other oxidants have been explored for the
synthesis of platinum(IV) anticancer agents. One such alternative oxidant is the
dithiobis(formamidinium) cation. The dichloride salt of the dithiobis(formamidinium) cation
oxidized cisplatin, adding a thiourea and a chloride to the axial positions (Scheme 21).291
The oxidation of trans-[Pt(NH3)2Cl2] with this reagent afforded initially the all trans isomer,
t,t,t-[PtCl2(NH3)2(tu)Cl], but over time it isomerized to give the same product obtained by
the oxidation of cisplatin, cis,cis,trans-[Pt(NH3)2Cl2(tu)Cl].292 Notably, the
tetrafluoroborate salt of the dithiobis(formamidinium) cation does not give any oxidation
products, thus highlighting the important role of the coordinating chloride counterion in
facilitating the oxidative addition.291,292 Bromine, like chlorine, also oxidizes diamine
platinum(II) complexes, generally forming trans dibromido complexes (Scheme 21).293 The
bromine oxidation of several dichlorido platinum(II) complexes, however, failed to give the
expected trans dibromido products; instead, a mixture of complexes with different ratios of
chloride and bromide ligands was obtained.250,294 For diphosphine complexes, this halide
scrambling reaction is initiated by light.295 Oxidations of cisplatin with KMnO4296 or
ozone297 in water reportedly both lead to the formation of the dihydroxo compound,
cis,cis,trans-[Pt(NH3)2Cl2(OH)2], which can also be obtained by oxidation with hydrogen
peroxide. The use of peroxydisulfate, S2O82−, as an oxidant, primarily gives trans hydroxo-
sulfato platinum(II) complexes.296,298 The reaction of diamine diamidate complexes of
platinum(II) with NaOCl yields the corresponding trans hydroxo-chlorido platinum(IV)
complexes (Scheme 21).299 The tetrachloroaurate ion, [AuCl4]−, can also oxidize
platinum(II). The complex cis-[Pt(NH3)2(1-methylthymine)2] was oxidized by NaAuCl4 to
afford cis,cis,trans-[Pt(NH3)2(1-methylthymine)2(OH)(OH2)].300 The addition of two
ligands originating from water was unexpected and rationalized on the basis of steric
crowding at the axial sites by the 1-methylthymine ligands. In contrast, the oxidation of a
platinum(II) terpyridine complex by AuCl4− added two chloride ligands to the resulting
platinum(IV) coordination sphere.301 Nitrogen dioxide gas can also oxidize cisplatin in an
aqueous solution containing one equiv of KCl (Scheme 21).302 The product, [PtCl3(NO2)
(NH3)], which could not be isolated as analytically pure material, comprised primarily the
facial isomer, as determined by NMR spectroscopy. Analysis by X-ray diffraction revealed a
disordered mixture of facial and meridional isomers.302 Potassium dichromate, K2Cr2O7,
and potassium chlorochromate, KCrO3Cl, can also oxidize cisplatin.303 On the basis of
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spectroscopic data, the products were proposed to be a dimetallic heteronuclear Pt–Cr
complex and a trimetallic Pt–Cr2 complex, respectively, with oxo ligands bridging the metal
centers (Scheme 21).303 Similarly, cisplatin was oxidized by iron(III) complexes of the
general formula, cis-[Fe(bpy')2(CN)2](NO3), where bpy' is derivative of 2,2'-bipyridine, to
form trinuclear cyanide-bridged complexes (Scheme 21).304,305 The photochemistry of these
complexes was explored, and in some cases the release of aquated cisplatin as a
photoproduct occurred,304,305 thus signifying the potential use of such complexes as
photoactivated anticancer agents.
Hypervalent iodine species are a class of powerful oxidizing agents with utility in organic
synthesis. Iodobenzene dichloride (PhICl2),306 which can be isolated as a crystalline solid,
acts as an easy-to-handle surrogate for chlorine gas. It efficiently converts cisplatin and
related diaminedichloridoplatinum(II) complexes to their corresponding
tetrachloridoplatinum(IV) analogues (Scheme 22).249,250 A recent report describes the
action of PhICl2 on an organoamide platinum(II) complex in a mixture of acetone and basic
water.307 A mixed trans hydroxo-chlorido platinum(IV) complex is obtained (Scheme
22),307 consistent with a solvent-assisted mechanism, similar to that observed for oxidations
by chlorine and hydrogen peroxide.
The oxidations of cis- and trans-[Pt(NH3)(NH2Cy)Cl2], where NH2Cy is cyclohexylamine,
with PhI(OAc)2 in dichloromethane have been investigated.308 The major products derive
from the oxidative addition of two acetate ligands in a cis orientation. For cis-[Pt(NH3)
(NH2Cy)Cl2], the major product is cis,cis,cis-[Pt(NH3)(NH2Cy)Cl2(OAc)2], whereas, when
the starting material is trans-[Pt(NH3)(NH2Cy)Cl2], the major product is cis,trans,cis-
[Pt(NH3)(NH2Cy)Cl2(OAc)2] (Scheme 22). In addition to the major product, minor products
mer-[Pt(NH3)(NH2Cy)Cl(OAc)3] and fac-[Pt(NH3)(NH2Cy)(OAc)Cl3] also form upon
PhI(OAc)2 oxidation of cis-[Pt(NH3)(NH2Cy)Cl2], indicative of intermolecular ligand
substitution reactions. The apparent limitations of using PhI(OAc)2 in contrast to PhICl2 are
the formation of products without predictable stereochemistry and unexpected ligand
stoichiometries. Given the large number of hypervalent iodine complexes in the literature,
further investigations of their reactivity with platinum(II) complexes is certainly warranted,
for they may lead to new, valuable synthetic routes to novel platinum(IV) complexes.
3.2. Outer-Sphere Ligand-Based Reactivity
Outer-sphere ligand-based reactivity pathways for the preparation of new platinum(IV)
complexes is a valuable synthetic route because their kinetic inertness limits the utility of
ligand substitution reactions. A reaction of key importance in this regard is that of Pt(IV)-
hydroxo compounds with electrophiles. The coordinated hydroxide ligand of platinum(IV)
complexes is sufficiently nucleophilic to enable such transformations. The acetylation of
cis,cis,trans-[Pt(iPrNH2)2Cl2(OH)2] with trifluoroacetic anhydride to form cis,cis,trans-
[Pt(iPrNH2)2Cl2(O2CCF3)2] was first demonstrated in 1983.309 This chemistry was further
expanded to include a broader range of acid anhydrides, pyrocarbonates, and isocyanates as
electrophiles to afford dicarboxylate, dicarbonate, and dicarbamate platinum(IV) complexes,
respectively.129 In all cases, the stereochemistry of the starting dihydroxo platinum(IV)
compound is retained. For acetylation of trans,trans,trans-[Pt(NH3)(NH2Cy)Cl2(OH)2] with
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acetic anhydride, however, light-induced isomerization of the initial product,
trans,trans,trans-[Pt(NH3)(NH2Cy)Cl2(OAc)2], to trans,cis,cis-[Pt(NH3)
(NH2Cy)Cl2(OAc)2] occurred.308
Since the initial report, a wide variety of trans platinum(IV) dicarboxylate complexes have
been synthesized in this manner. The carboxylate ligands have significant effects on both the
lipophilicity and reduction potentials of the resulting platinum(IV) complexes.310–313
Furthermore, the ubiquitous nature of the carboxylate functional group in many different
organic molecules enabled the synthesis of platinum(IV) complexes bearing biologically
active ligands, attached via the carboxylate.314–317 Different protocols have called for the
use of excess anhydride, either neat,129 or together with acetone,129 dichloromethane,66,310
acetonitrile,318,319 or DMSO320,321 as the solvent (Scheme 23). Similarly, tetracarboxylato
platinum(IV) complexes, some of which exhibit anticancer activity when administered
orally,322 can be synthesized from cis-[PtL2(OH)4]293,308,323 and excess anhydride in
dichloromethane (Scheme 23).308,324 This reaction demonstrates that equatorial cis
hydroxide ligands also display nucleophilic properties. Acyl chlorides also react with trans
dihydroxo platinum(IV) complexes to form dicarboxylates. A difficulty in this reaction,
noted early on,129 is the formation of hydrochloric acid as a byproduct, which can remove
the hydroxo ligands of platinum(IV) by protonation. Optimized reaction conditions utilize
refluxing acetone as a solvent and an excess of pyridine as a base to sequester the HCl that is
formed (Scheme 23).325,326 Aromatic carboxylate ligands can be installed on platinum(IV)
with this method as well.314,327
A third route to trans platinum(IV) dicarboxylates utilizes the ring opening reactions of the
platinum(IV) hydroxo complexes with cyclic anhydrides. Succinic,154,328,329 maleic,154,245
glutaric,154,330 phthalic,327 and naphthalic331 anhydrides have all been used in this reaction,
together with the traditional Chinese medicine cantharidin.315 Early protocols for this
reaction involved the treatment of a platinum(IV) hydroxo compound with the cyclic
anhydride in refluxing dichloromethane for two days.154,330 Currently, the most commonly
used method utilizes either DMF329 or DMSO328 as solvent at 50–80 °C for 6–24 h
(Scheme 23). Activating carboxylic acids with an appropriate coupling reagent has also been
an effective means of forming trans dicarboxylate complexes. For example, the reaction of a
platinum(IV) analogue of oxaliplatin, trans-[Pt(trans-1,2-DACH)(oxalate)(OH)2], with 3
equiv of carboxylic acid, triethylamine (TEA), and the coupling reagent O-benzotriazol-1-
yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) readily yields the dicarboxylato
complex, trans-[Pt(trans-1,2-DACH)(oxalate)(O2CR)2] (Scheme 23).288 This one pot
procedure may provide a useful alternative to the abovementioned methods because it
avoids the need to prepare anhydrides or acyl chloride as intermediates.
The synthesis of mixed platinum(IV) carboxylate complexes can introduce greater
molecular complexity and provide a means of installing different functional or targeting
groups. The reaction of a platinum(IV) dihydroxo complex with a mixture of different
anhydrides gives rise to a statistical mixture of symmetric and asymmetric platinum(IV)
dicarboxylates that can be separated by silica gel chromatography.129 Similarly, mixed
tetracarboxylates were synthesized by the reaction of a platinum(IV) tetrahydroxo complex
with different ratios of anhydrides.332 The resulting products required purification by either
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silica gel chromatography or preparative reverse-phase HPLC.332 Another, more elegant
pathway to mixed platinum(IV) dicarboxylates requires the isolation of a trans mixed
hydroxo-carboxylato platinum(IV) complex. The remaining hydroxo ligand could then be
derivatized with a different carboxylate ligand. The synthesis of several mixed hydroxo-
carboxylato complexes by the peroxide oxidation of platinum(II) in the presence of an
excess of carboxylic acid was described above, as shown in Scheme 19.261,288 These
complexes can react with another acid anhydride to yield a mixed-dicarboxylate complex.
The selective acetylation of a single hydroxo ligand is another potential strategy. One way to
accomplish this selective reaction is with steric control. Initially, the acetylation of a
platinum(IV) analogues of sterically hindered picoplatin, cis,cis,trans-[Pt(NH3)(2-
pic)Cl2(OH)2], with acetic anhydride was reported to be unsuccessful because the ortho
methyl group of the picoline ligand impedes the hydroxo nucleophilic attack.145 It was later
shown, however, that the acetylation of this complex can be successfully executed with a
number of different anhydrides to give symmetric dicarboxylate complexes.333 Thus the
steric effects of the 2-picoline ligand did not successfully lead to the formation of the
monohydroxo complex. The platinum(IV) complex cis,cis,trans-[Pt(en')Cl2(OH)2], where
en' is N,N-dimethylethylene-diamine, is selectively acetylated at only one of the hydroxo
ligands in the presence of excess succinic anhydride (Scheme 24).334 The inability to form
the dicarboxylate was attributed to steric repulsion induced by the additional methyl groups
on the ethylenediamine ligand.334 This strategy was expanded with other bulky derivatives
of ethlyenediamine to selectively functionalize only one hydroxide ligand with isocynates
and acyl chlorides using mild reaction conditions.335 The isolation of other mixed hydroxo-
carboxylato platinum(IV) complexes as synthons for mixed dicarboxylates was described
recently.331 These complexes were obtained by careful control of the reaction conditions.
The room temperature reactions of platinum(IV) dihydroxo complexes with an acid
anhydride in DMSO were used to increase the yield of the desired monocarboxylate
complexes with respect to that of the dicarboxylate species (Scheme 24). These reaction
conditions were employed to prepare complexes with axial aromatic carboxylates331 and
succinate.258,336 In general, the desired mixed hydroxo-carboxylato complexes are insoluble
in acetone, thereby enabling the undesired dicarboxylate complexes to be removed by
dissolution in this solvent.129 An alternative procedure utilizes a carboxylic acid
preactivated by N, N'-dicyclohexylcarbodiimide (DCC).288 The one pot reaction of a trans-
[Pt(trans-1,2-DACH)(oxalate)(OH)2] with only slightly greater than one equiv of DCC and
a carboxylic acid in DMF at room temperature preferentially gave the monocarboxylato
species (Scheme 24).288
In addition to acid anhydrides and acid chlorides, several other electrophiles react with
platinum(IV) hydroxo complexes. The reactivity of platinum(IV) hydroxides with
pyrocarbonates and isocyanates to form platinum(IV) carbonates and carbamates has been
known for over 15 years.129 The reactions of cis, cis, trans-[Pt(NH3)2Cl2(OH)2] with both
alkyl and aromatic isocyanates were recently investigated in detail.337 The optimal
conditions utilized four equiv of the isocyanate and DMF as the solvent at room temperature
for several hours (Scheme 25). The action of trimethylsilyl chloride (TMSCl) on the
tetrahydroxo complex, cis-[Pt(DPDA)(OH)4] has also been explored.323 At room
temperature in THF with TEA as a base, the main reaction product is the trans disiloxide
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complex, cis, trans, cis-[Pt(DPDA)(OSiMe3)2(OH)Cl], whereas refluxing conditions
afforded cis, trans, cis-[Pt(DPDA)(OSiMe3)2Cl2] (Scheme 25)323. The substitution of the
hydroxide ligands most likely arises from the HCl byproduct, which acts as the source of
protons to labilize the hydroxide ligands and as the source of the nucleophilic chloride
ligands.
The additional axial ligands available in platinum(IV) but not platinum(II) complexes can be
selected for introducing reactive organic functionalities. For example, the ring-opening
reaction of platinum(IV) hydroxides with cyclic acid anhydrides yields platinum(IV)
complexes with free terminal carboxylic acids. The terminal carboxylic acids can undergo
amide and ester coupling reactions with the octahedral platinum(IV) center remaining intact
(Scheme 26). These reactions have been used to covalently modify platinum(IV) complexes
with estrogen,328–341 and nano-delivery devices.274,342–348 Additionally, a wide variety of
amines and alcohols have been coupled to such platinum(IV) complexes in order to
systematically adjust their lipophilicities.284,329,349–354 For coupling reactions carried out in
DMF, N, N'-diisopropylcarbodiimide (DIPC),328O-(7-azabenzotriazol-1-yl)-N, N, N', N'-
tetramethyluronium hexafluorophosphate (HATU),342 and 1,1'-carbonyldiimidazole
(CDI)329 were all used with success, whereas for aqueous coupling reactions the
combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) (EDC) and N-
hydroxysuccinimide (NHS) works well.336,338,341
Two platinum(IV) complexes with axial ligands containing aldehyde and ketone functional
groups have also been reported recently.355,356 The reaction of these functional groups with
organic hydrazines and hydroxylamines leads to the formation of hydrazones and oximes,
providing a new convenient method to conjugate platinum(IV) to different units (Scheme
26). This strategy has already been employed to attach platinum(IV) to a short peptide356
and a polymeric nanoparticle.355 A platinum(IV) complex containing an axial carboxylate
ligand with a pendant azide has also recently been described.288 In the presence of CuI, the
azide ligand reacts with an alkyne to form the expected triazole, and the intact platinum(IV)
complex can be isolated by preparative HPLC in approximately 50% yield (Scheme 26).288
A possible limitation of this reaction for use in the preparation of other platinum(IV)
complexes could be undesired reduction of the platinum(IV) center by the Cu(I) ion. In
another recent report, a thiol-reactive maleimide functional group was installed in the axial
positions of two platinum(IV) complexes via carbamate linkages.357 The maleimide was
used to attach the platinum(IV) complex to human serum albumin at its single exposed
cysteine residue (Scheme 26).357
3.3. Ligand Substitution Reactions
Because of the inert nature of platinum(IV) complexes, direct ligand substitution reactions
are generally very slow and require harsh conditions. As a result, such reactions are rarely
employed to prepare anticancer platinum(IV) prodrug candidates. Complexes of the type
[Pt(L2)Cl4], where L2 is a chelating diamine ligand, however, can be synthesized by the
reaction of the [PtCl2]2− anion with L2 in water, usually under refluxing conditions.358–362
For more complicated structures, different strategies can be utilized to facilitate ligand
substitution of platinum(IV), as discussed below.
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Hydroxide ligands bound to platinum(IV) complexes can be substituted under acidic
conditions. A popular synthetic route to cis-[Pt(NH3)2Cl4] and other diamine tetrachlorido
complexes utilizes cis, cis, trans-[Pt(NH3)2Cl2(OH)2] as a platinum(IV) starting material.
Treatment of this compound with hydrochloric acid affords the tetrachloride (Scheme
27).310 This reaction most likely proceeds via protonation of the hydroxo ligands, converting
them to labile water ligands, followed by displacement with the nucleophilic chloride ion.
This reaction also works for hydrobromic acid to substitute bromide for hydroxide
ligands.363 When hydrochloric acid is added to the tetrahydroxo compound, [Pt(trans-1,2-
DACH)(OH)4], all four hydroxides are replaced by chloride ligands.364 In contrast,
suspending [Pt(trans-1,2-DACH)(OH)4] in neat carboxylic acid affords the trisubstituted
species, fac-[Pt(trans-1,2-DACH)(OH)(O2CR)3] (Scheme 27).364 It is hypothesized by the
authors of these studies that the pKa of the last hydroxide ligand is too low to be protonated
by a carboxylic acid (pKa ≈ 5), but not lower than that of the stronger acid HCl. This
hydroxo ligand, however, still retains its nucleophilic character as it can be acetylated with
other carboxylic anhydrides to rationally make mixed carboxylate complexes.365 When
trifluoroacetic anhydride is added to these tricarboxylate complexes in the absence of a base,
the unexpected product cis, cis, cis-[Pt(trans-1,2-DACH)(O2CR)2(O2CCF3)2] is obtained
(Scheme 27).366 The hydroxide is most likely initially acetylated by trifluoroacetic
anhydride, releasing the strong acid, trifluoroacetic acid, as a byproduct. Trifluoroacetic acid
can then protonate and release a coordinated carboxylate ligand and bind to the platinum(IV)
center. Consistent with this hypothesis is the observation that adding a base with the
trifluoroacetic anhydride gives rise only to the expected complex, fac-[Pt(trans-1,2-DACH)
(O2CCF3)(O2CR)3], presumably by neutralizing the trifluoroacetic acid byproduct.366
Just as acidic conditions favor ligand substitution reactions in platinum(IV) complexes by
protonolysis, basic conditions can also induce ligand substitution, albeit by a different
mechanism. Under basic conditions, platinum amine complexes can undergo ligand
substitution via the base hydrolysis mechanism.367–369 In general, these reactions result in
the net substitution of a chloride by a solvent ligand. The first step is the deprotonation of an
amine ligand to form an amido ligand. The high trans effect of the amido ligand favors
dissociation of a trans chloride ligand, yielding a five-coordinate intermediate. The addition
of a solvent molecule to this five-coordinate intermediate results in the observed product. In
the realm of platinum-based anticancer agents, this reaction mechanism has been proposed,
albeit without supporting kinetic data, for the formation of several new derivatives of
satraplatin.308,370 The reaction of cis, cis, trans-[Pt(NH3)(NH2Cy)Cl2(O2CC3H7)2] with
sodium methoxide in methanol resulted in substitution of the chloride trans to the
cyclohexylamine for a methoxide ligand, forming cis, cis, trans-[Pt(NH3)(NH2Cy)Cl(OMe)
(O2CC3H7]2 (Scheme 28)370. Similarly, in basic water cis, cis, trans-[Pt(NH3)
(NH2Cy)Cl2(O2CCH3)2] converts to the monohydroxide complex, cis, cis, trans-[Pt(NH3)
(NH2Cy)Cl(OH)(O2CCH3)2], where the hydroxide ligand is also trans to the
cyclohexylamine (Scheme 28).308 In DMA containing 2 M LiCl, the addition of TEA as a
base to cis-[Pt(NH3)(NH2Cy)(OAc)4] afforded the monochlorido complex mer-[Pt(NH3)
(NH2Cy)Cl(OAc)3] (Scheme 28).308 In this case, the base hydrolysis route was able to
substitute an acetate ligand rather than a chloride. This reaction also demonstrates that, if a
non-coordinating solvent is used, other ligands besides solvent can be added to the
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platinum(IV) complex. In a recent study, it was demonstrated that platinum(IV) complexes
with electronegative halocarboxylate ligands can be directly hydrolyzed, undergoing
substitution of the carboxylates for hydroxides.371 These reactions are accelerated under
basic conditions,371 suggesting that a conjugate base mechanism might be operative.
4. Concluding Remarks
The chemistry of cisplatin and its isomers was first explored over one hundred years ago.
The discovery of its anticancer properties in 1969 motivated further exploration into its
coordination chemistry and that of related species,372,373 with the ultimate goal of finding
new complexes with improved therapeutic properties. The development of new synthetic
methodologies can give access to new platinum complexes with novel structures and
possibly novel modes of biological activity. This review summarizes the known reactivity
patterns and synthetic strategies for a range of platinum anticancer complexes. Notably,
much of this chemistry has only been developed within the last 20 years. Thus, as long as
the need for new platinum anticancer agents persists, new chemistry will be developed and
investigated in order to obtain such compounds.
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bpy 2,2'-bipyridine
CBDCA 1,1-cyclobutanedicarboxylato
CDI 1,1'-carbonyldiimidazole
DACH diaminocyclohexane
dien diethylenetriamine
DMA N,N-dimethylacetamide
DCC N,N'-dicyclohexylcarbodiimide
DPDA 2,2-dimethyl-1,3-propanediamine
DIPC N,N'-diisopropylcarbodiimide
DPP diphenyl phosphate
edda ethylenediamine-N,N'-diacetic acid
edma ethylenediaminemonoacetic acid
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide)
edta ethylenediametetraacetic acid
en ethylenediamine
fpd 9-fluorenylidenepropanedioate
HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
pmpa N-(2-picolyl)picolinamide
NHS N-hydroxysuccinimide
TBTU O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate
TEA triethylamine
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TMSCl trimethylsilyl chloride
tu thiourea
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Chart 1.
Chemical structures of the clinically used platinum-based anticancer drugs. The top three complexes, cisplatin, carboplatin, and
oxaliplatin, are approved for use worldwide. The bottom three complexes, nedaplatin, lobaplatin, and heptaplatin, are approved
for use in Japan, China, and Korea, respectively.
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Chart 2.
Structures of mixed amine platinum(II) complexes that have undergone clinical trials.
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Chart 3.
Examples of cationic monofunctional platinum(II) complexes that exhibit anticancer activity.172–174
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Chart 4.
Depiction of the six different stereoisomers of [PtCl2(iminoether)2]. The terms cis and trans refer to the stereochemistry at the
platinum(II) center, whereas E and Z denote the stereochemistry at the C–N double bond of the iminoether ligands.213
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Chart 5.
Examples of several clinically investigated platinum(IV) anticancer agents.
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Figure 1.
Different components of platinum anticancer agents. Additional factors that can be varied are the stereochemistry and the
respective number of non-leaving and leaving group ligands.
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Scheme 1.
Synthesis of cisplatin using the method of Dhara.60 All reactions steps are carried out in aqueous solution.
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Scheme 2.
The use of the Kurnakow test81 to distinguish cis- and trans-[Pt(NH3)2Cl2]. Reactions with thiourea are carried out in sub-
boiling water.
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Scheme 3.
Synthesis of trans-[Pt(NH3)2Cl2].57 Reactions are carried out in water at elevated (50–100 °C) temperatures.
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Scheme 4.
Different synthetic routes to replace halide leaving group ligands.95,107
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Scheme 5.
Synthesis of cis-[Pt(NH3)LCl2] starting from cisplatin using the [Pt(NH3)Cl3]− ion as an intermediate.126,130
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Scheme 6.
Synthesis of mixed amine complexes, cis-[PtLL'I2], via iodido-bridged dimer intermediates.131,142
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Scheme 7.
Synthesis of mixed amine complexes with a chelating oxygen donor leaving group.152
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Scheme 8.
Synthesis of trans-[PtLL'Cl2].158
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Scheme 9.
Synthesis of [Pt(NH33Cl]Cl.169
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Scheme 10.
Two different synthetic routes for the preparation of cis-[Pt(L2)(RR'SO)Cl]Cl.173
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Scheme 11.
Synthesis of cis-[Pt(NH3)2LCl]NO3.172,189
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Scheme 12.
Synthesis of monofunctional, thiourea platinum(II) complexes.208
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Scheme 13.
Synthesis of cis- (top), trans-[PtCl2(iminoether)2] (middle), and trans-[PtCl2(imino thioether)2].213,219,221
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Scheme 14.
Synthesis of cis- (top) and trans-[PtCl2(amidine)2] (middle).229 Room temperature conditions and extended reactions times lead
to the formation of primarily trans-[Pt(NH2R')2(amidine)2] from trans-[PtCl2(NCR)2] (bottom).235
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Scheme 15.
Multi-step synthetic scheme for the preparation of monofunctional platinum-amidine complexes.236
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Scheme 16.
Condensation reactions involving the coordinated ammine ligands of cis- and trans-[Pt(NH3)2Cl2], as well as their diiodido
analogues.244,246
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Scheme 17.
Outer-sphere ligand-based reactivity pathways of several platinum(II) complexes.248–253
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Scheme 18.
Oxidation of a platinum(II) complex with chlorine (top)264 and hydrogen peroxide266 (bottom). The products obtained for the
hydrogen peroxide-oxidation are dependent on the solvent used.273,274
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Scheme 19.
Peroxide oxidations of platinum(II) complexes in various acidic solvents.261,285,286,288
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Scheme 20.
Ring-closing oxidation reactions of [Pt(edma)Cl2] (top),248 [Pt(edda)Cl2] (middle),248,289 and [Pt(edta)Cl2] (bottom).290
Wilson and Lippard Page 64
Chem Rev. Author manuscript; available in PMC 2015 April 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Scheme 21.
Preparation of platinum(IV) complexes using different oxidizing agents.291–293,299,303–305
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Scheme 22.
Oxidation of platinum(II) complexes with hypervalent iodine reagents.307,308
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Scheme 23.
Synthetic methods for the preparation of platinum(IV) carboxylates.129,288,324,325,328
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Scheme 24.
Synthesis of mixed trans hydroxo-carboxylato platinum(IV) complexes.258,288,331,336
Wilson and Lippard Page 68
Chem Rev. Author manuscript; available in PMC 2015 April 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Scheme 25.
Reactivity of platinum(IV) hydroxides with electrophiles.129,323,337
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Scheme 26.
Outer-sphere reactivity of platinum(IV) complexes with organic functional groups.288,328,329,355–357
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Scheme 27.
Ligand substitution reactions facilitated by acidic conditions.310,364,366
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Scheme 28.
Ligand substitution reactions facilitated by basic conditions, presumably through a base hydrolysis mechanism.308,370
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